Revance Therapeutics Inc (RVNC)

[vinmantoo]

It’s going to be an uphill battle for sure. CD is a very small portion of a therapeutic market. They should have gone after the migraine market first.

The market for CD is certainly large enough to make a big difference in RVNC's fortunes and a longer lasting toxin will make a far bigger difference to those suffering from CD than for cosmetic purposes. That means uptake in CD should be much faster. I believe migraines would be a harder and more expensive indication for clinical trials. Whether or not they should have pursued that area instead of glabellar lines and CD or in addition to both is now a moot point. The market size for CD is shown below along with projections for future growth.

https://www.businessresearchinsights.com/market-reports/cervical-dystonia-therapeutics-market-103393

I am sure there will be off label use of the product. The hard part is where it falls on the insurance formularies.

Yes, there will be off-label usage in therapeutics.